Literature DB >> 8983270

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

S S Bielack1, R Erttmann, B Kempf-Bielack, K Winkler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8983270     DOI： 10.1016/0959-8049(96)00177-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  11 in total

1.  Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

Authors:  W Linkesch; M Weger; I Eder; H W Auner; C Pernegg; C Kraule; M J Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

2.  Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells.

Authors:  Gisela Kersting; Mladen V Tzvetkov; Klaus Huse; Bettina Kulle; Verena Hafner; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-07       Impact factor: 3.000

Review 3.  Ewing tumour: incidence, prognosis and treatment options.

Authors:  M Paulussen; B Fröhlich; H Jürgens
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: effect of doxorubicin and hypothermia.

Authors:  Wonku Kang; Michael Weiss
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

Review 5.  Safety aspects of pegylated liposomal doxorubicin in patients with cancer.

Authors:  D S Alberts; D J Garcia
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 6.  Anthracyclines in the treatment of cancer. An overview.

Authors:  G N Hortobágyi
Journal:  Drugs       Date:  1997       Impact factor: 9.546

7.  Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.

Authors:  Sigbjørn Smeland; Oyvind S Bruland; Lars Hjorth; Otte Brosjö; Bodil Bjerkehagen; Gustaf Osterlundh; Ake Jakobson; Kirsten Sundby Hall; Odd R Monge; Olle Björk; Thor A Alvegaard
Journal:  Acta Orthop       Date:  2011-03-24       Impact factor: 3.717

8.  TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

Authors:  A H van der Veen; J H de Wilt; A M Eggermont; S T van Tiel; A L Seynhaeve; T L ten Hagen
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Platycodin D from Platycodonis Radix enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells.

Authors:  Zheng-Hai Tang; Ting Li; Hong-Wei Gao; Wen Sun; Xiu-Ping Chen; Yi-Tao Wang; Jin-Jian Lu
Journal:  Chin Med       Date:  2014-06-09       Impact factor: 5.455

10.  Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.

Authors:  Christian Siebel; Gudrun Würthwein; Claudia Lanvers-Kaminsky; Nicolas André; Frank Berthold; Ilaria Castelli; Pascal Chastagner; François Doz; Martin English; Gabriele Escherich; Michael C Frühwald; Norbert Graf; Andreas H Groll; Antonio Ruggiero; Georg Hempel; Joachim Boos
Journal:  BMC Pharmacol Toxicol       Date:  2020-05-28       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.